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Background: Over 50% of colorectal cancer (CRC) patients develop metastases. The aim of this study was to
evaluate efficacy and tolerance of first-line FOLFIRI® + bevacizumab (B) treatment for metastatic CRC, and to assess
genetic polymorphisms as potential markers.
Methods: Adult patients with histologically-proven, non-resectable metastatic CRC and ECOG≤ 2 were included.
14-day cycles consisted of bevacizumab (5 mg/kg), irinotecan (180 mg/m2), bolus FU (400 mg/m2) and leucovorin
(400 mg/m2), followed by 46-hour FU infusions (2400 mg/m2). Primary endpoint was response rate according to
RECIST criteria. Secondary endpoints were overall (OS) and progression-free (PFS) survivals, response duration, and
toxicity. Associations between clinical data, UGT1A1, thymidylate synthase, VEGFA polymorphisms and PFS, OS and
toxicity were analyzed.
Results: Sixty-two patients were enrolled (median age 68y). 59/62 patients were eligible and evaluable for response
at 6 months: 28 showed partial response (47.5%; 95% CI; 34.3-60.9), 20 stable disease (33.9%) and 11 progression
(18.6%). Grade 3/4 toxicities were as follows: neutropenia 16.1%; diarrhea 11.3%; nausea-vomiting 1.6%. Median
response duration was 9.5 months (range 2.7-20); median PFS 10.3 months (range 8.8-11.7); and median OS
25.7 months (range 20.2-29.7). 11/59 initially unresectable patients were resectable after treatment. VEGFA
polymorphism (rs25648) was associated with better OS (HR: 3.61; 95% CI: 1.57-8.30).
Conclusions: FOLFIRI® + bevacizumab is active with good response rate, long median OS, and a good safety profile.
A VEGFA polymorphism might have a prognostic value in this malignancy.
Trial registration: Clinicaltrials.gov: NCT00467142 (registration date: April 25, 2007)
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Colorectal cancer (CRC) is a major public health problem.
Its incidence in France is increasing [1] with approximately
40 000 new cases per year [2] and prognosis remains poor
[3]. Over 50% of patients will develop metastases and will
be candidates for palliative chemotherapy [4]. Bevacizumab
is a monoclonal antibody directed against the vascular
endothelial growth factor (VEGF). It has proven efficacy in* Correspondence: y.becouarn@bordeaux.unicancer.fr
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unless otherwise stated.the treatment of metastatic CRC when combined with
chemotherapy [5-7]. Irinotecan, infusional 5-fluorouracil
(FU), leucovorin (LV) (FOLFIRI®) and bevacizumab (FOL-
FIRI® + B) offered better outcomes when compared to iri-
notecan plus infusional fluorouracil (FU)/leucovorin (LV)
(FOLFIRI®), irinotecan plus bolus FU/LV (mIFL), and irino-
tecan plus oral capecitabine (CapeIRI) in a randomized
trial [5]. However, a relatively high rate of ≥Grade 3 hyper-
tension was observed.
Several gene polymorphisms may interfere with anti-
cancer drug activity, and thus affect drug efficacy and
toxicity. For FU, a thymidylate synthase promoter 28-bpral Ltd. This is an Open Access article distributed under the terms of the Creative
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cacy and increased toxicity [8]. For irinotecan, a UGT1A1
promoter TA repeat (rs8175347) is a risk factor for tox-
icity [9]. For Bevacizumab, several VEGFA single nucleo-
tide polymorphisms (SNP) are known to influence VEGFA
plasma concentrations [10] and to be associated with CRC
risk [11]. In addition, prognostic [12,13] and predictive
[14,15] roles of VEGFA variants have been identified in
various studies.
The principal objective of this phase II trial was to evalu-
ate efficacy of first-line treatment with FOLFIRI® + B for
metastatic CRC patients in terms of response rates. Second-
ary objectives were to assess overall and progression-free
(PFS) survivals, response duration, and toxicity. We also ex-
plored common gene polymorphisms known to interfere
with the metabolism and/or activity of FOLFIRI® + B, lo-
cated respectively in the thymidylate synthase (TYMS),
UDP-glucuronosyltransferase 1A1 (UGT1A1) and VEGFA
genes, looking for associations between these polymor-
phisms and the clinical parameters of toxicity and efficacy
of the treatment.
Methods
Patients for this open-label, single arm, phase II trial
were recruited from Institut Bergonié, the University
Hospital of Bordeaux, and five general hospitals and pri-
vate clinics in South-West France.
Inclusion criteria were: histopathologically-proven
adenocarcinoma of the colon or rectum, non-resectable
metastatic disease; no prior chemotherapy other than
adjuvant chemotherapy (provided it had been discontin-
ued > 6 months before study entry); Eastern Cooperative
Oncology Group (ECOG) performance status ≤ 2; age ≥
18 years; measurable metastatic disease per Response
Evaluation Criteria in Solid Tumors (RECIST Version 3.0)
[16]; adequate hematological function [hemoglobin ≥10 g/
dl, absolute neutrophils count ≥1.5 × 109/l, platelets ≥100 ×
109/l]; adequate renal function [no proteinuria and creatin-
ine ≤1.25 × the upper limit of the normal value (ULN)];
adequate hepatic functions [total bilirubin ≤1.25 ×ULN, as-
partate amino-transferase (AST) and alanine aminotrans-
ferase (ALT) ≤3 ×ULN, in case of liver metastases, total
bilirubin ≤1.5 ×ULN and AST and ALT ≤5 ×ULN]; inter-
vals since inclusion of 4 weeks for eventual surgery or
radiotherapy; ability to comply with scheduled follow-up
and management of toxicity.
Exclusion criteria included: histology other than adeno-
carcinoma; non-measurable disease; adjuvant chemo-
therapy within 6 months or containing Bevacizumab;
unresolved bowel or partial bowel obstruction; history
of chronic diarrhea; severe gastrointestinal toxicity while re-
ceiving FU; current uncontrolled infection; serious illness or
medical condition; previous abdominopelvic radiation ther-
apy; known Gilbert’s syndrome; arterial thromboembolismaccident or myocardial infarction within preceding 6months;
history of cancer other than colorectal, except for curatively
treated non-melanoma skin cancer or in-situ cervical can-
cer; concomitant treatment with any other investigational
drug; and pregnancy.
The protocol was approved by the regional Ethics Review
Committee (Comité de Protection des Personnes du Sud-
Ouest et d’Outre-Mer) and registered with clinicaltrials.gov
(NCT00467142, registration date April 25, 2007). Each pa-
tient provided written informed consent. For the comple-
mentary pharmacogenetic study, patients were enrolled on
a voluntary basis and gave specific consent.
Treatment
FOLFIRI® + B treatment consisted of a 90-min I.V. infusion
of bevacizumab (5 mg/kg) followed by a 90-min I.V. infu-
sion of irinotecan (180 mg/m2) followed by a simplified
LV5FU2 regimen [leucovorin (400 mg/m2) and bolus fluo-
rouracil (400 mg/m2) on day 1 and a 46-h infusion of fluo-
rouracil (2400 mg/m2)]. Treatment was delivered biweekly.
FOLFIRI® doses were adjusted in the event of toxic ef-
fects (National Cancer Institute Common Terminology
Criteria for Adverse Events, NCI–CTCAE, version 3.0
[17], according to the following guidelines. Hematological
toxicity was evaluated during each cycle. In the event of
myelosuppression (i.e. absolute neutrophils count <1.5 ×
109/l and/or platelets <75 × 109/l) at the planned date for
the next cycle of chemotherapy, treatment was postponed
for 1 to 3 weeks until recovery. After a 4-week delay with
no recovery, the patient left the study. In the event of re-
covery, the FU bolus at day 1 was deleted if the toxicity
was related to the neutrophils count. The continuous FU
infusion at day 1 and 2 was reduced by 25% if the toxicity
was related to the platelet count. The same dose reductions
were implemented in the event of grade 4 neutropenia or
thrombocytopenia, or grade 3 neutropenia associated with
fever. After two dose reductions, patients left the study. In
the event of grade 3 or 4 diarrhea, the irinotecan dose was
reduced to 150 mg/m2 and the FU bolus was deleted at
day 1. In the event of a second episode of severe diarrhea,
the continuous FU infusion was reduced by 25%. In the
event of grade 3 or 4 mucositis or hand-foot syndrome, a
25% dose reduction of FU bolus and FU continuous infu-
sion was carried out.
Bevacizumab dose was not reduced. For severe drug-
induced toxicities, treatment was stopped, either tem-
porarily or indefinitely. In the case of gastrointestinal
perforation, grade 3 or 4 hemorrhage, thromboembolic
accidents, severe hypertension or grade 4 proteinuria,
bevacizumab was stopped indefinitely.
Assessment methods
Pre-inclusion work-up included an initial radiologic as-
sessment within the 3 weeks before treatment onset, and



















Lymph nodes 16 (25.8)
Peritoneum 17 (27.4)
Others 14 (22.5)
Number of organs involved (measurable)
1 8 (12.9)
2 12 (19.3)
≥ 3 42 (66.1)
Adjuvant chemotherapy 17 (27.4)
Radiotherapy 8 (12.9)
Surgery 50 (80.6)
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before inclusion. The first administration occurred within
8 days of inclusion. During treatment, clinical and bio-
logical assessments were conducted on day 1 of each 14-
day cycle. Radiologic assessment was carried out every
four cycles (8 weeks) with centralized external secondary
review. Treatment toxicity was evaluated before each cycle
(NCI–CTCAE v3). Treatment was discontinued in the
event of disease progression, unacceptable toxicity or pa-
tient refusal. Patients were followed-up every 3 months
after treatment discontinuation.
Genotyping
DNA was extracted from blood samplings obtained after
patient inclusion and collection of informed consent.
We used the kit QIAamp® DNA purchased from Qiagen
according to the instructions of the manufacturer. Geno-
typing of DNA extracts was performed using a customized
platform, SNPChip484, enabling simultaneous determin-
ation of 384 selected SNP from a DNA extract. It consists
of a collection of kits containing the primers specific for
each SNP, prepared upon demand by Illumina and used
according to the BeadXpress Goldengate-Veracode tech-
nology. Rough genotyping results were treated and ana-
lyzed using the Genome Studio software from Illumina,
which enables the individual determination for each
DNA sample of the genotype of all 384 SNPs. Although
we genotyped 384 different SNPs, we analyzed only the
results concerning the three VEGFA polymorphisms
that were scheduled in the protocol: rs699947 (−2578C >
A), rs2010963 (−634G >C), rs25648 (S178S, formerly
known as -7C > T) in order to avoid statistical problems
associated with multiple testing.
Genotyping of UGT1A1 and TYMS
The variations in the TYMS gene were determined using
RFLP techniques [18]. The TA repeat in the UGT1A1
promoter (UGT1A1-28 genotype, rs8175347) was deter-
mined by pyrosequencing performed after PCR amplifica-
tion with the following primers: sense: 5′GAACTCCCTG
CTACCTTTGTG3′), antisense (biotinylated): 5′TTTGC
TCCTGCCAGA GGTT3′. PCR products were analyzed
without further purification on a Pyrosequencer PyroMark
ID system (Qiagen, Courtaboeuf, France) according to
the instructions of the manufacturer with the following
sequencing primer: 5′ TCGATTGGTTTTTGC3′. The
SQA mode was used to analyze the TA repeat. The vari-
ations in the TYMS gene were determined using RFLP
techniques as follows: for the 3′UTR insdel polymorph-
ism (rs16430), PCR was performed using the following
primers: sense: 5′- CAAATCTGAGGGAGCTGAGT-3′;
antisense: 5′-CAGATAAGTGGCAGTACAGA-3′. The
PCR products were digested by DraI, which specifically
cleaves the +6 allele, and subjected to polyacrylamide gelelectrophoresis. For the 5′UTR tandem repeat variation in
the TYMS gene promoter (rs34743033), PCR was per-
formed using the following primers: sense: 5′-AGGC
GCGCGGAAGGGGTCCT-3′; antisense: 5′-TCCGAGCC
GGCCACAGGCAT-3′. The 2R/3R variation was first
identified by direct electrophoresis of the PCR products
on 12% polyacrylamide gels; the PCR products were then
digested by HaeIII, which specifically cleaves the 3G allele,
and subjected to polyacrylamide gel electrophoresis.
Statistical considerations
A two-stage Simon’s design was used. Using unacceptable
and acceptable response rates of 50% and 70% respectively,
a 5% type I error rate and a 10% type II error rate (90%
power), the total sample size for this trial was 61 assessable
patients over two stages, with 24 assessable subjects re-
cruited during the first stage. At the end of the first stage,
14 PR/CR were required to continue. At the end of the sec-
ond stage, 37 PR/CR were required to conclude efficacy.
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rate (RR) at 6 months (both partial [PR] and complete
[CR]), evaluated according to RECIST as reviewed by an in-
dependent expert committee. Secondary endpoints were
progression-free survival (PFS), response duration, overall
survival (OS) and toxicity. PFS was calculated from the time
of inclusion to disease progression or death of any cause,
and duration of the time of the documented response to
the progression date. OS was calculated from the first treat-
ment cycle to death (of any cause). PFS and OS were calcu-
lated by the Kaplan-Meier method. Median follow-up was
calculated with the reverse Kaplan-Meier method. Univari-
ate analyses were performed to determine factors associated
with higher OS, PFS and toxicity from clinical and pharma-
cogenetic data. A Fisher’s exact test was used to evaluate
the association of investigated genotypes, clinical data and
toxicity. The associations between genotypes, clinical data
and survival were tested using the log-rank test. The effects
on OS and PFS were estimated by hazard ratios (HRs) (Cox
proportional hazards regression model), with adjustment
for clinical and pathological factors. All tests were two-
sided, and a P value of less than 0.05 was considered statis-
tically significant. In order to take into account the multiple
testing that was performed, the final P-values are adjusted
to control for a False Discovery Rate (FDR) of 5% [19]. All
variables significant at P = 0.05 (after adjustment for poly-
morphisms) were included in the multivariate models. Stat-
istical analysis was carried out using SAS V9.2 (Cary, NY).Figure 1 Overall survival for colorectal cancer patients treated with F
confidence interval, CI).Three populations were defined for analysis: for the
primary response criteria, this included all eligible pa-
tients with tumoral evaluation by scan and review at six
months, for toxicity this included all patients receiving
at least one dose of the FOLFIRI® + B treatment and for




Sixty-two patients were enrolled in this trial between
January 2007 and August 2009 (Table 1). One patient who
had been treated 2 years earlier for a squamous cell vocal
cords tumor was considered a major protocol violation
and excluded from the survival and response analyses.
Two other patients were not evaluable for the primary re-
sponse endpoint (one was lost to follow-up before the CT
scan evaluation; the second stopped treatment due to a
cause not related to the trial). They all received at least
one dose of the FOLFIRI® + B treatment and are included
for toxicity analyses.
Response and survival
At the cut-off date of December 2011, median follow-up
was 43.6 months (range: 26.3–45 months) and no pa-
tient was still receiving treatment. Responses were evalu-
ated at 6 months for 59 eligible and assessable patients,
with 28 patients achieving a partial response (objectiveOLFIRI® and bevacizumab in first-line treatment (with 95%
Figure 2 Progress-free survival for colorectal cancer patients treated with FOLFIRI® and bevacizumab in first-line treatment (with 95%
confidence interval, CI).
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disease (33.9%), and 11 with progressive disease (18.6%).
The median duration of response was 9.5 months (range:
2.7-20). Median OS was 25.7 months (95% CI; 20.2-29.7)
and median PFS was 10.3 months (95% CI; 8.8-11.7). At
one year, survival was 85% (95% CI; 73.2-91.9%), and PFS
was 35% (95% CI; 23.3-47]) (Figures 1–2). Eleven patients
could subsequently be resected following treatment.
Tolerance
Chemotherapy administration was generally compliant.
Relative dose intensity was higher than 90% for each drug
(Irinotecan 94.5%, FU 93.8% and bevacizumab 94.5%). A
total of 1058 cycles were administered (median 13, range
3–62) with median cumulative doses of 2200.5 mg/m2 for
irinotecan, 34.624 g/m2 for FU and 60.9 mg/kg for bevaci-
zumab. Cycle delays (i.e. delay in schedule ≥ 8 days) were
observed for 28 patients (43.5%), for toxicity in all cases
but one (mainly hematological or diarrhea). Five patients
(8%) stopped treatment for toxicities. Fourteen patients
(22.6%) stopped therapy for surgical procedures. Nine ser-
ious adverse events linked to treatment were observed for
seven patients (11.3%): (3 diarrhea, 2 colitis, 1 renal failure,
1 gastritis, 1 phlebitis, and 1 leukocytes).All 62 patients were assessable for toxicity. No toxic
deaths occurred (Table 2). A toxic effect (of any grade)
led to dose modifications for 32 patients (51.6%) over
the first 20 cycles of treatment.
Genotyping
Fifty eight patients (94%) agreed to participate in the phar-
macogenetic study and material was received for 46 pa-
tients. One major protocol exclusion was observed leaving
45 eligible patients for genotyping. The detailed results of
genotyping are presented in Additional file 1. No signifi-
cant deviations from the Hardy-Weinberg equilibrium
were noticed for any. Concerning the VEGFA genotype, it
was possible to detect a significant linkage disequilibrium
between the two promoter polymorphisms, but the exonic
SNP (rs25648) was not in linkage disequilibrium with the
two other SNPs. Concerning the TYMS genotype, there
was a linkage disequilibrium between the 3′UTR insdel
variation and the 5′UTR tandem repeat, which was of
borderline significance. After correction for multiple test-
ing, not one of the polymorphisms studied was associated
with toxicity or PFS but the S178S synonymous variation
(rs25648) was significantly associated with OS (rough P-
value = 0.0013, corrected P-value = 0.0104, HR = 0.605,
Table 2 Drug-related toxicity per patient for colorectal
cancer patients treated with FOLFIRI® and bevacizumab





N (%) N (%)
Neutropenia 11 (17.7) 10 (16.1)
Febrile neutropenia 0 – 0 –
Anemia 4 (6.5) 0 –
Thrombocytopenia 1 (1.6) 0 –
Nausea 20 (32.3) 1 (1.6)
Vomiting 6 (9.7) 0 –
Diarrhea 19 (30.6) 7 (11.3)
Stomatitis/mucositis 16 (25.8) 2 (3.2)
Neurosensory 1 (1.6) 1 (1.6)
Asthenia 3 (4.8) 4 (6.4)
Gastrointestinal perforation 0 – 0 –
Hypertension 1 (1.6) 0 –
Venous thromboembolism 3 (4.8) 0 –
Proteinuria 8 (12.9) 0 –
Bleeding 7 (11.3) 0 –
Alopecia 10 (16.1) 0 –
*NCI-CTCAE - National Cancer Institute Common Terminology Criteria for
Adverse Events v3.0.
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ation with PFS, it appeared significant (P-value = 0.049)
only before correction for multiple testing.
In univariate analysis VEGFA rs25648 polymorphism,
sex, serum alkaline phosphatase (ALP) and lactate de-
hydrogenase (LDH) were significantly associated with
OS. In multivariate analysis, sex (P = 0.0136), serum
ALP (P = 0.0085) and the VEGFA rs25648 polymorph-
ism (P = 0.0041) remained significant (Table 3).
Discussion
The primary objective of this trial was to assess the ob-
jective response rate after treatment with FOLFIRI® + B
in metastatic CRC. We observed 47.5% objective partial
responses with no complete responses at six months.
These results appear slightly higher than the most recent
phase III trial report with 142 patients showing a response
rate of 40.1% [20], similar to as reported by Souglakos
et al. [21] (45.5%), and higher than reported in a recent
phase III trial (36.8% [22], although they are lower than in
previous studies (eg. BICC-C [5] or Kopetz et al. [23]) with
59% and 65% objective responses respectively.
With a median follow-up time of 43.6 months, the me-
dian PFS was 10.3 months, and one-year PFS was 35%.
This supports previous reports after FOLFIRI® + B treat-
ment with PFS reported between 9 [24] to 11.6 months
[25], and 12.8 months [23]. The median OS in thepresent trial was 25.7 months, with a one-year survival
of 85%. Once again, these rates support previously and
recently published rates with OS reported between
22 months [22] 23.7 months [25], 25.7 [21], 28 months
(one-year OS of 87%) [26] and 31.3 months [23]. In a re-
cent observational report involving over 240 patients,
median PFS was reported at 10.2 months and median
OS at 25.5 months, once again providing further support
for these patterns [27]. Our results show that a curative
hepatic surgery could be carried out for 11 patients
(18.6%) that were judged to be unresectable before FOL-
FIRI + B treatment. The rate of hepatic surgery with FOL-
FIRI® + B was not reported in the BICC-C study [5,26],
and it was 6.5% in the Beat Study Cohort and 9.3% in
Kopetz et al.’s study [23].
In randomized trials in patients with metastatic CRC,
bevacizumab has been shown to improve response rates,
OS and PFS when combined with chemotherapy regimens
like bolus FU/LV [28], irinotecan plus bolus FU/LV (IFL)
[6] and oxaliplatin plus infusional FU/LV (FOLFOX) [29].
In a systematic review for patients with advanced CRC re-
ceiving first- or second-line fluoropyrimidine-based chemo-
therapy, the addition of bevacizumab improved PFS and
OS, although toxicity was also increased [30]. A more re-
cent systematic review and meta-analysis including over
3000 patients from randomized trial [31] shows a distinct
advantage for PFS when bevacizumab is added. In subgroup
analyses, the effect was strongest for FU- and irinotecan-
based chemotherapy regimens and less marked in
oxaliplatin-based regimens.
Severe toxic effects were mainly hematologic and less
frequently gastrointestinal. The rate of grade ≥3 toxicities
was low. At 19.4%, neutropenia was the most frequent se-
vere toxicity, as has been described in other trials [20], al-
though the rate was lower than described in other studies
at (53.6%) [5] or (40%) [23]. The rate of severe diarrhea
(11.3%) was similar to the BICC-C study (10.7%) [5] and
higher than in Kopetz’s study (2%) [23]. Considering ad-
verse events which could be related to bevacizumab, we
had no gastrointestinal perforation compared to 0% [5,23]
to 2% [25] reported in the literature; no severe bleeding
compared to 0% [5,23] -3% [25], no Grade 3/4 proteinuria,
similar to 1% in Van Cutsem et al. [25]; no severe hyper-
tension, lower than reported in the literature at 5% [25] to
12.5% [5] and 19% [23]; and 1.6% Grade 3/4 venous
thromboembolism events compared to 1% [25] and 19%
[23]. It should be noted that for the 11 patients who
were operated on in this trial, no delayed wound healing
was noted, with bevacizumab being stopped six weeks
before surgery.
Associations between TYMS polymorphisms and FU ef-
ficacy and toxicity in CRC have been reported in several
studies [32-35] but not all [36]. In our study, no influence
of TYMS polymorphisms on the efficacy or toxicity of the
Figure 3 Overall survival for genotypes C and H of the rs25648 polymorphism for colorectal cancer patients with FOLFIRI® and
bevacizumab in first-line treatment (with 95% confidence interval, CI).
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population tested as well as the fact that the patients did
not receive exclusively FU probably explain the lack of as-
sociations. The toxicity of irinotecan has been associated
with a polymorphism of the SN-38-detoxifying enzyme,
UGT1A1, located in the promoter of the gene [37].
However, the risk of experiencing irinotecan-induced
hematological toxicity appears to be a function of the
dose administered [37]; the risk is higher at the dose usually
prescribed in the US (340 mg/m2 every 3 weeks) than at the
dose prescribed in Europe (180 mg/m2 every two weeks).
This may also explain the lack of associations in our study.
We found an association between OS and the presence
of a polymorphic exonic synonymous variation in the
VEGFA gene. Interestingly, the rs25648 variation is one of
the three SNPs influencing VEGF serum levels [38], as
well as VEGFA mRNA levels in colorectaladenocarcinoma [39]. One could hypothesize that the
higher levels of VEGFA produced by the variant allele
limits the efficacy of the anti-VEGF antibody and, there-
fore, has an impact on patient survival. However, the as-
sociation of this polymorphism with outcome was only
significant for OS and not for PFS, which would indicate
a general prognostic impact rather than a predictive role
for bevacizumab efficiency. Studies involving a larger
number of patients should be undertaken with a special
focus on this polymorphism which has not been studied
extensively up to now.
The fact that a synonymous polymorphism in the cod-
ing sequence of VEGFA exerts an effect on VEGF levels
in plasma may be explained by a difference in the 3-
dimension structure or the half-life of the transcribed
mRNA, which may introduce differences in its handling
by the translation machinery. Alternatively, the
Table 3 Univariate and multivariate analyses for demographic, clinical and genetic data with overall survival for
colorectal cancer patients treated with FOLFIRI® and bevacizumab (n = 45)
Univariate Multivariate
N (45) HR [95% CI] P HR [95% CI] P (Wald)
Sex: Male 16 (35.6) ref. ref. ref.
Female 29 (64.4) 0.43 [0.20; 0.90] 0.02 0.38 [0.18; 0.82] 0.01
Age, y: <=65 20 (44.4) ref.
> 65 25 (55.6) 1.09 [0.52; 2.28] 0.81 - -
ECOG/PS: 0 16 (35.6) ref.
1-2 29 (64.4) 1.26 [0.60; 2.70] 0.55 - -
Primary tumor: Colon 28 (62.2) ref.
Rectum 17 (37.8) 1.16 [0.56; 2.40] 0.69 - -
Non-mucinous: No 5 (11.1) ref.
Yes 40 (88.9) 0.45 [0.15; 1.36] 0.15 - -
Metastatic sites: 1 13 (28.9) ref.
>1 32 (71.1) 0.77 [0.36; 1.65] 0.50 - -
Liver-only metas.: No 33 (73.3) ref.
Yes 12 (26.7) 1.14 [0.52; 2.52] 0.74 - -
Resected primary tumor: No 10 (22.2) ref.
Yes 35 (77.8) 0.67 [0.29; 1.51] 0.33 - -
Previous adjuvant CT*: No 34 (75.6) ref.
Yes 11 (24.4) 0.85 [0.36; 1.98] 0.70 - -
High ALP†: No 23 (51.1) ref. ref. ref.
Yes 19 (42.2) 2.80 [1.25; 6.26] <0.009 4.21 [1.44; 12.31] 0.008
High LDH§: No 16 (35.6) ref.
Yes 13 (28.9) 4.73 [1.42; 15.81] <0.006 1.46 [0.62; 3.43] 0.39
High ACE††: No 17 (37.8) ref.
Yes 22 (48.9) 2.07 [0.91; 4.72] 0.08 - -
rs25648: C 34 (75.6) ref. ref. ref.
H/V 11 (24.4) 3.605 [1.57;8.30] 0.01** 3.58 [1.50; 8.57] 0.004
rs2010963: C 17 (37.8) ref.
H/V 28 (62.2) 1.228 [0.59;2.56] 0.58 - -
rs699947: C 34 (75.6) ref.
H/V 11 (24.4) 1.324 [0.59;2.99] 0.50 - -
rs8175347: C 15 (33.3) ref.
H/V 30 (66.7) 0.632 [0.30;1.35] 0.23 - -
3′UTR: C 23 (51.1) ref.
H/V 22 (48.9) 1.298 [0.64;2.63] 0.47 - -
5′UTR: V 11 (24.4) ref.
C/H 33 (73.3) 0.972 [0.44;2.13] 0.94 - -
5′UTR: C 13 (28.9) ref.
H/V 31 (68.9) 0.886 [0.41;1.91] 0.76 - -
*CT = chemotherapy.
**P-value corrected to false discovery rate of 5% [19].
†ALP = alkaline phosphatase, Missing: 3 (6.7).
§LDH = lactate Dehydrogenase, Missing: 16 (35.6).
††ACE = angiotensin-converting Enzyme, Missing: 6 (13.3).
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http://www.biomedcentral.com/1756-0500/7/260difference in tRNA availability because of the use of a
rare codon may lead to a decrease in translation rate,
and thus to a reduced production of the protein.
Some limits should be taken into account when inter-
preting this data. Firstly, the non-comparative nature of
this non-randomized phase II trial should be kept in mind
when comparing efficacy results. It should also be noted
that although we found a significant effect for the primary
endpoint of objective response, no complete responses
were observed.Conclusions
The present results support the growing body of evidence
from phase II [24], phase III and observational studies in-
dicating that FOLFIRI® + B is an active and safe treatment
for first-line treatment of metastatic colorectal cancer,
with almost half of patients showing an objective response
and comparatively long median OS. Further, almost 1/5
initially unresectable patients became resectable after
treatment, offering potential for longer survival. It has a
good safety profile, with relatively low rates of thrombo-
embolism compared to other alternative chemotherapy
associations. The association between the genetic poly-
morphism rs25648 and improved OS is encouraging,
but needs to be confirmed in further trials.Additional file
Additional file 1: Distribution of the genotypes of the 6
polymorphisms determined in 46 patients for colorectal cancer patients
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